Table 2. Patient characteristics.
| Characteristics |
ALL202-U (n=139) |
ALL97a (n=104) |
P-value |
|---|---|---|---|
| No. (%) | No. (%) | ||
| Sex | |||
| Male | 78 (56) | 58 (56) | |
| Female | 61 (44) | 46 (44) | 0.957 |
| Age | |||
| Median | 19 | 19 | |
| Age <20 | 83 (60) | 54 (52) | |
| Age ⩾20 | 56 (40) | 50 (48) | 0.226 |
| PS | |||
| 0–1 | 128 (92) | 93 (89) | |
| 2–4 | 11 (8) | 11 (11) | 0.474 |
| WBC count (/μl) | |||
| Median | 10 500 | 11 480 | |
| WBC <50 000 | 104 (75) | 79 (76) | |
| WBC ⩾50 000 | 35 (25) | 25 (24) | 0.838 |
| Serum LDH level | |||
| Normal | 20 (14) | 14 (13) | |
| Elevated | 119 (86) | 90 (87) | 0.415 |
| Phenotype | |||
| CD19+, CD10- | 18 (13) | 20 (19) | |
| CD10+ | 89 (64) | 69 (66) | |
| CD19−, CD7+ | 31 (22) | 14 (14) | 0.591b |
| Unknown | 1 (1) | 1 (1) | |
| Karyotypec | |||
| Standard risk | 2 (1) | 5 (5) | |
| Intermediate risk | 110 (79) | 74 (71) | |
| High risk | 11 (8) | 7 (7) | |
| Very high risk | 15 (11) | 7 (7) | 0.322b |
| Unknown | 1 (1) | 11 (10) | |
| Chimera mRNA | |||
| E2A-PBX1 | 6 (5) | ||
| SIL-TAL1 | 4 (3) | ||
| TEL-AML1 | 2 (2) | ||
| MLL-AF4 | 1 (1) | ||
| MLL-ENL | 1 (1) | ||
| CNS involvement | |||
| Negative | 128 (95) | 103 (99) | |
| Positive | 7 (5) | 1 (1) | 0.072 |
Abbreviations: CNS, central nervous system; LDH, lactic acid dehydrogenase; PS, performance status; WBC, white blood cell.
a
Ph-negative patients under 25 years were extracted.
b
Analyzed excluding unknown cases.
c
Modified MRC UKALLXII/ECOG E2993ALL cytogenetic subgroups.